AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05375916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Sustained-release hydromorphone is a long-acting preparation opioid
Study NCT05375916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Sustained-release hydromorphone is a long-acting preparation opioid
Study NCT05440032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Semi-quantitative electrochemical leukocyte esterse test strip
Description: Electrochemical assay to detect level of leukocyte esterase in sample
Study NCT05440032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Roche Chemstrip
Description: Urinalysis chemstrip
Study NCT05224830 — intervention group
Intervention type: OTHER
Intervention: Nijmegen questionnaire score
Description: We collected the Nijmegen Questionnaire in order to diagnosis of Hyperventilation Syndrome
Study NCT06045117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioPumlonary Management System (CPM)
Description: The CPM Device measures and trends a variety of physiologic parameters including thoracic impedance, respiration rate, tidal volume, ECG (electrocardiogram), heart rate, and diastolic heart sounds, all in an unobtrusive patch form factor.
Study NCT06222268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) only
Description: Cannabis consisting of 2.5mg CBD and 0mg Delta-9-tetrahydrocannabinol (THC) is delivered through a vaporizer.
Study NCT06222268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo only
Description: Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
Study NCT06222268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-tetrahydrocannabinol (THC) only
Description: Cannabis containing 2.5mg THC and 0mg CBD is delivered through a vaporizer.
Study NCT06222268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC:CBD 1:1
Description: Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
Study NCT06222268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC:CBD 1:10
Description: Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
Study NCT06194916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: A 4-WEEK SELF-MANAGEMENT TRAINING WILL BE PROVIDED THROUGH THE WEB-BASED TRAINING SITE.
Study NCT06194916 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: THEY WILL RECEIVE THE ROUTINE CARE GIVEN TO PATIENTS WITH EPILEPSY.
Study NCT06120725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: Efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg bid for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT06120725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Efficacy and safety of 300 mg clopidogrel followed by 75 mg once daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study NCT05805436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Patients in the intervention arm will take polyethylene glycol 3350 for three days before robotic urologic surgery. Patients in the control arm will not.
Study NCT06274372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flow controlled ventilation
Description: effects of flow controlled ventilation
Study NCT06274372 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: volume controlled ventilation
Description: effects of volume controlled ventilation
Study NCT04620304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UB-421 SC(dB4C7C22-6 mAb)
Description: The UB-421 SC (dB4C7C22-6 mAb) will be supplied at a concentration of 125 mg/mL after reconstitution. Subjects will receive weekly UB-421 SC injections during the 4-week Treatment Period.
Study NCT05520333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIPAS Alcohol
Description: Weekly text messages for three months.
Study NCT05828342 — intervention group
Intervention type: PROCEDURE
Intervention: Endotracheal tube cuff inflation with the loss of resistance syringe method
Description: The cuffs of the endotracheal tubes will be inflated with the epidural loss of resistance syringe, the syringe piston will be released, the syringe piston will be pushed back with oscillation, and then the cuff pressures will be measured and recorded with a cuff manometer (VBM Cuff Pressure Gauge) and an electronic injector that measures cuff pressure (AG Cufill). A three-way vein valve will be used when making this measurement. During the measurement, an epidural resistance loss injector will be attached to one valve, a cuff manometer attached to another valve, and an electronic injector (AG Cufill) measuring cuff pressure to the third track. With this technique, the possibility of leakage due to insertion and removal during measurements will be eliminated.
Study NCT06208813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Creatine supplementation
Study NCT04867759 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Biopsy
Description: On outpatient basis, we will take a uterine sample on mid-luteal phase day 21 by Novac curette or pipelle aspirator. Samples of endometrium will be kept in formaline solution and will be sent to National Institute of research and medical sceinces at Alexandria University to be tested for uNK Cells CD56.
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liftactiv® B3 Serum
Description: In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liftactiv® B3 Serum
Description: In Group 1: Application once daily for 6 months, 3-4 drops twice a day (morning before the sunscreen and evening) In Group 2 and Group 3: Application once daily, 3-4 drops twice a day (morning before the sunscreen and evening) for 3 months following HQ4% or Kligman Trio treatment.
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liftactiv® B3 retinol night cream
Description: In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liftactiv® B3 retinol night cream
Description: In Group 1: Application once daily (morning) for 6 months In Group 2 and Group 3: During week 1, apply 2 evenings/week. During week 2, apply every other evening. During week 3, apply every evening. During nights when retinol night cream is not applied, replace with Mineral 89 cream for 3 months following HQ4% or Kligman Trio treatment.
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen UVAage® Inter SPF 50+
Description: twice daily (morning and beginning of the afternoon)
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen UVAage® Inter SPF 50+
Description: twice daily (morning and beginning of the afternoon)
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mineral 89 cream
Description: 2 drops in the morning before sunscreen application for 6 months
Study NCT06516224 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral 89 cream
Description: 2 drops in the morning before sunscreen application for 6 months
Study NCT02937376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cystein
Description: A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
Study NCT02937376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A trial of exercise before and after 4 weeks of placebo administration.
Study NCT04610775 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Order of cuff sizes during blood pressure measurements
Description: Each participant will have 4 sets of 3 blood pressure measurements taken. The participants will be randomized to the order in which the cuff sizes are used.
Study NCT05424341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: For Gastrocnemius muscle, subject will be in supine position keeping knee fully extended and therapist on affected side in walking position. The subject's ankle joint will be dorsiflexed until a resistance feel and will ask to hold this position and exert 20% of force towards plantar flexion for a period of 5 to 7 seconds. Resistance will be released and relaxation of 5 seconds will be given during which the ankle will was passively dorsiflexed to a new barrier. 5 repetitions will be given.
Study NCT05424341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counterstrain Technique
Description: Therapist places thumb on tender point at plantar fascia insertion while patient in supine position with ipsilateral knee flexed. Plantar flex the toes and ankle while monitoring sore site with thumb, curling around tender point until monitoring thumb feels symptomatic relief. Supination/pronation of foot will be added if necessary. The position of ease will be maintained for 90 secs until tissues beneath monitoring thumb softens. Tender spot is re-evaluated once the foot is returned to neutral without moving the thumb. It will be repeated 3 times for 30 secs resting interval in-between
Study NCT06313645 — intervention group
Intervention type: OTHER
Intervention: Several biomarkers
Description: Telomere length Mitochondrial DNA copy number (mtDNAcn) MitomiR long non-coding (lnc) RNA TERRA pro-oxidant cytokines \& chemokines
Study NCT04625283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Participants in the ketamine arm will receive intraoperative and postoperative ketamine.
Study NCT04625283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo arm will receive intraoperative and postoperative saline.
Study NCT04794907 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Patient data will be collected from eye exams, surveys and medical record review.
Study NCT05706324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
Description: 0.2mL/dose, Inhalation using a nebulizer
Study NCT05164211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didgeridoo
Description: the children will have 6 didgeridoo lessons given by a teacher spread over 3 months.
Study NCT05841511 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese handwriting intervention program for children with ASD, named Go Go Handwriting - ASD version
Description: The intervention program was developed and finalized by a group of occupational therapist specialists in the pediatric field. Thirty-six 20-minute activities with twelve activities for each handwriting fundamental skill were designed in this program.~All intervention activities were designed based on the characteristic of Chinese characters and included different types of characters.~The activities designed will also be graded according to the following principle: (1) the similarities between the character given, (2) the complexity of the figure or character in the activities, and (3) the frequency and level of therapist assistance.~Furthermore, a playful and interesting intervention context will also be integratedinto the program with the design of the adventure journey of an astronaut to further facilitate the motivation and participation of the participants in our program.
Study NCT04761003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopy forceps
Description: take pleural biopsy
Study NCT05751551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized, home-based motor-cognitive training
Description: The simultaneous motor-cognitive training in this study will be conducted in form of exergames (interactive video games) using Senso hardware (DIV-SENSO-H, Dividat GmbH, Schindellegi, Switzerland) - a stepping platform with 5 pressure sensitive plates which is connected to a screen. For the home-based training, a more mobile version of the Dividat Senso will be used: a foldable pressure-sensitive mat. In both devices, stimuli of exergames appear on the screen and the participants have to react by stepping in one of 4 directions (front, back, left, right).~The motor-cognitive training approach allows targeting different cognitive functions such as attention, executive functions, memory, and visuo-spatial functions as well as balance, and strength.~FITT-VP principles will serve as a guideline but based on the functional status of each participant (physical and cognitive), the training sessions will be personalized in terms of training content, intensity and duration.
Study NCT05115799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy, Physiotherapy, Kinesiology, Scar Massage
Description: The physiotherapist performs passive kinesitherapy on the mastectomized patient with lymphatic thrombus, and scar massage when the arm maintains its greater range of mobility.~The patient will never present pain during the rehabilitation session above 5 in Pain Scale Analog Scale.
Study NCT05115799 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Kinesiotherapy, Physiotherapy, Health Education
Description: These users will be instructed in hygienic-postural care and active auto-kinesitherapy assisted to perform daily for 30 minutes. The investigators will value following the instructions every 30 days
Study NCT05635201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia induction with propofol
Description: After a 10-minute-long acclimation, general anesthesia is induced with 2% propofol at the effect-site concentration of 4 μg/ml based on the Marsh Pharmacokinetic model. The effect-site concentration was maintained at 4 μg/ml until the trachea was intubated. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentrations of propofol and remifentanil were decreased to 3 μg/ml and 0 ng/ml, respectively, until the surgical incision was made.
Study NCT05635201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia induction with remimazolam
Description: After a 10-minute-long acclimation, general anesthesia is induced with a 2-minute-long infusion of remimazolam at a rate of 12 mg/kg/hr, after which the infusion rate was reduced to 1 mg/kg/hr and was maintained until the surgical incision was made. Five minutes after the anesthesia induction, remifentanil was administered at the effect-site concentration of 4 ng/ml based on the Minto pharmacokinetic model until the trachea was intubated. With the initiation of remifentanil infusion, 1 mg/kg of rocuronium was administered following the calibration of the neuromuscular monitoring device. With the train-of-four count of 0, the trachea was intubated. Then, the effect-site concentration of remifentanil was decreased to 0 ng/ml until the surgical incision was made.
Study NCT05777655 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication management app (mediteo m+, Mediteo GmbH, Heidelberg)
Description: Free access to a study version of the medication management app mediteo m+ for reminders and documentation of statin therapy in addition to usual care
Study NCT05397418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise program
Description: 12 week supervised low impact resistance training program
Study NCT05397418 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Unsupervised resistance exercise program
Description: 12 week unsupervised low impact resistance training program
Study NCT05397418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised resistance exercise program
Description: 12 week unsupervised low impact resistance training program
Study NCT05968105 — intervention group
Intervention type: PROCEDURE
Intervention: Lateral Sagittal Infraclavicular Block
Description: Patients will be in the supine position and after aseptic conditions are provided, the axillary artery of the patient will be visualized in the craniocaudal plane, in the infraclavicular region and in the lateral sagittal position with the help of an 8-12 mHz linear probe. After the brachial plexus cords around the axillary artery are identified, a local anesthetic mixture will be applied in-plane between the posterior cord and the artery. During the block, patients will routinely be given a mixture of 0.25% bupivacaine + 0.5% lidocaine 0.5 mL/kg.
Study NCT05968105 — intervention group
Intervention type: PROCEDURE
Intervention: Inferior vena cava diameter >1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) < 50%
Description: While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
Study NCT05968105 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inferior vena cava diameter <1.5 cm and Vena Cava Inferior Collapsibility Index (VCI-CI) > 50%
Description: While the patients are lying in the supine position, the vena cava will be determined 2 cm before the inferior heart entrance with the help of a 3.5-5 mHz convex probe. M-mode ECHO will be used to determine the fluctuation rate of the VCI between inspiration and expiration. After determining the farthest and closest points in M-mode ECO, their ratios to each other will be calculated.
Study NCT05264116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRYKER SUSTAINABILITY SOLUTIONS PULSE OXIMETERS
Description: Reprocessed noninvasive pulse oximeter sensors.
Study NCT06013566 — intervention group
Intervention type: DEVICE
Intervention: SSVEP
Description: Non-invasive, non-interventional SSVEP EEG device
Study NCT05115396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: The patient shall be seated in a chair with a table in front of him/her. On the table there is a mirror in the sagittal plane between the two upper extremities. The affected hand will be behind the mirror, without visibility, while the hand without symptoms will be reflected laterally in the mirror. Thus, the mirror will reflect the movements of the unaffected side as if these movements were executed with the affected side. During the procedure, patients will be instructed to concentrate on the hand reflected in the mirror.
Study NCT05115396 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-education treatment
Description: Participants will perform the same exercise protocol with the unaffected hand and without the use of a mirror.
Study NCT05192642 — intervention group
Intervention type: DRUG
Intervention: Larotrectinib(Vitrakvi, BAY2757556)
Description: Clinical trials
Study NCT05192642 — intervention group
Intervention type: DRUG
Intervention: Data on other treatments
Description: Real word data
Study NCT05278897 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft Tissue Adapted Biocompatible Hyaluronic Acid
Description: 1% sodium hyaluronate
Study NCT05244200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and insulin staging.
Description: Pharmaceutical care is a patient-centered practice in which the practitioner assumes responsibility for a patient's drug-related needs and is held accountable for this commitment. Due to the progressive nature of Type 2 Diabetes Mellitus, which requires timely optimization of treatment, leading in a majority of cases to insulin therapy, so that proper use of insulin is one of the critical tools for prevention of long-term complications. From the hundred patients in this study, half of the patients will be the control group without any intervention, and pharmaceutical care and insulin staging will be applied on the remaining. In this research two strategies will be applied including pharmaceutical care process and Insulin Staging approach on patients with T2DM, those who are on end stage treatment.
Study NCT05188105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha tACS (12 Hz) over the occipital cortex
Description: Single session of alpha tACS (12 Hz) over the occipital cortex
Study NCT05188105 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Alpha tACS (12 Hz) over the occipital cortex
Description: Single session of alpha tACS (12 Hz) over the occipital cortex
Study NCT05689437 — intervention group
Intervention type: OTHER
Intervention: Application of ILD prediction machine learning model to planning imaging
Description: The ILD prediction machine learning model will be applied to the treatment planning imaging of lung cancer patients receiving radiation therapy (RT). The model will score the risk as high risk or low risk for having underlying ILD.